Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enoxacin
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Enoxacin is a broad-spectrum, orally active fluoroquinolone antibiotic used primarily for the treatment of urinary tract infections and gonorrhea. It acts as a bactericidal agent by inhibiting bacterial DNA gyrase (DNA topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination in bacteria. This inhibition prevents the untwisting of DNA required for replication and cell division. Enoxacin is effective against both Gram-positive and Gram-negative bacteria, including some strains resistant to other antibiotics with different mechanisms of action. The drug is rapidly absorbed after oral administration with high bioavailability and achieves high concentrations in the urinary tract[1][2][3][4][5][6][7]. Developed as part of the quinolone class, it has also been studied for its effects on microRNA processing via TRBP-dependent pathways[8].
- Brand names
- Penetrex
- Other names
- enoxacinum
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on enoxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enoxacin.